Aprea Therapeutics (NASDAQ:APRE) Director Purchases $25,107.03 in Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey bought 21,459 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were purchased at an average cost of $1.17 per share, with a total value of $25,107.03. Following the completion of the transaction, the director owned 256,155 shares in the company, valued at $299,701.35. This represents a 9.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Aprea Therapeutics Trading Up 5.7%

Shares of APRE traded up $0.05 during midday trading on Thursday, reaching $0.96. 49,285 shares of the stock were exchanged, compared to its average volume of 51,825. The company has a market capitalization of $6.08 million, a P/E ratio of -0.45 and a beta of 1.23. Aprea Therapeutics, Inc. has a 52 week low of $0.90 and a 52 week high of $5.00. The company’s 50 day moving average is $1.31 and its two-hundred day moving average is $1.55.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative net margin of 2,666.46% and a negative return on equity of 88.12%. The firm had revenue of $0.00 million during the quarter. On average, sell-side analysts expect that Aprea Therapeutics, Inc. will post -2.55 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aprea Therapeutics currently has a consensus rating of “Hold” and an average target price of $15.50.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.